09/01/2025 16:00
Toshiba to Showcase the Next Generation of Retail Innovations at First NRF Retail’s Big Show in Europe

Toshiba Global Commerce Solutions will showcase how the latest retail innovations are empowering retailers to craft unique journeys and sustainably deliver success in booth #G167 - Pavilion 6 at the first-ever NRF 2025: Retail’s Big Show Europe this month. Toshiba’s new modular and customized solutions utilize advanced technology like AI, computer vision, and machine learning to meet the unique needs of retailers, no matter their size or segment. This press release features multimedia. View th...

09/17/2025 19:46
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commiss...

09/18/2025 15:45
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As pa...

09/18/2025 09:20
Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites

Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qua...

09/18/2025 10:41
European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary

European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head...

09/18/2025 07:30
Acuity Knowledge Partners Acquires Ascent

Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating ...

09/18/2025 12:30
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment optio...

09/18/2025 05:00
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydratio...

09/18/2025 06:00
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance

Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202509...

09/18/2025 06:00
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025

Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the impor...